These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

375 related items for PubMed ID: 21270669

  • 21. [Survival status of stage IV non-small cell lung cancer patients after radiotherapy--a report of 287 cases].
    Cai Y, Wang WL, Xu B, Zhu GY, Zhang SW.
    Ai Zheng; 2006 Nov; 25(11):1419-22. PubMed ID: 17094913
    [Abstract] [Full Text] [Related]

  • 22. Incidence and survival from lung cancer in Greenland is comparable to survival in the Nordic countries.
    Gelvan A, Risum S, Langer SW.
    Dan Med J; 2015 Apr; 62(4):A5033. PubMed ID: 25872548
    [Abstract] [Full Text] [Related]

  • 23. Site of Metastases as Prognostic Factors in Unselected Population of Stage IV Non-Small Cell Lung Cancer.
    Ashour Badawy A, Khedr G, Omar A, Bae S, Arafat W, Grant S.
    Asian Pac J Cancer Prev; 2018 Jul 27; 19(7):1907-1910. PubMed ID: 30051671
    [Abstract] [Full Text] [Related]

  • 24. Predictors of skeletal-related events in non-small cell lung cancer patients with bone metastases.
    Sun JM, Ahn JS, Lee S, Kim JA, Lee J, Park YH, Park HC, Ahn MJ, Ahn YC, Park K.
    Lung Cancer; 2011 Jan 27; 71(1):89-93. PubMed ID: 20598769
    [Abstract] [Full Text] [Related]

  • 25. Metastatic non-small cell lung cancer: costs associated with disease progression.
    Fox KM, Brooks JM, Kim J.
    Am J Manag Care; 2008 Sep 27; 14(9):565-71. PubMed ID: 18778171
    [Abstract] [Full Text] [Related]

  • 26. Factors Associated With Treatment of Clinical Stage I Non-Small-cell Lung Cancer: A Population-based Analysis.
    Berry MF, Canchola AJ, Gensheimer MF, Gomez SL, Cheng I.
    Clin Lung Cancer; 2018 Sep 27; 19(5):e745-e758. PubMed ID: 30149883
    [Abstract] [Full Text] [Related]

  • 27. Phase II study of pemetrexed and cisplatin, with chest radiotherapy followed by docetaxel in patients with stage III non-small cell lung cancer.
    Gadgeel SM, Ruckdeschel JC, Patel BB, Wozniak A, Konski A, Valdivieso M, Hackstock D, Chen W, Belzer K, Burger AM, Marquette L, Turrisi A.
    J Thorac Oncol; 2011 May 27; 6(5):927-33. PubMed ID: 21415776
    [Abstract] [Full Text] [Related]

  • 28. Cost-effectiveness of denosumab compared with zoledronic acid in patients with breast cancer and bone metastases.
    Xie J, Diener M, Sorg R, Wu EQ, Namjoshi M.
    Clin Breast Cancer; 2012 Aug 27; 12(4):247-58. PubMed ID: 22694824
    [Abstract] [Full Text] [Related]

  • 29. Concurrent chemotherapy and short course radiotherapy in patients with stage IIIA to IIIB non-small cell lung cancer not eligible for radical treatment: results of a randomized phase II study.
    Nawrocki S, Krzakowski M, Wasilewska-Tesluk E, Kowalski D, Rucinska M, Dziadziuszko R, Sowa A.
    J Thorac Oncol; 2010 Aug 27; 5(8):1255-62. PubMed ID: 20592630
    [Abstract] [Full Text] [Related]

  • 30. Healthcare utilization and costs associated with skeletal-related events in prostate cancer patients with bone metastases.
    Hagiwara M, Delea TE, Saville MW, Chung K.
    Prostate Cancer Prostatic Dis; 2013 Mar 27; 16(1):23-7. PubMed ID: 23146970
    [Abstract] [Full Text] [Related]

  • 31. Long-term results of a phase II trial of induction paclitaxel-carboplatin followed by concurrent radiation therapy and weekly paclitaxel and consolidation paclitaxel-carboplatin in stage III non-small cell lung cancer.
    Casas F, Viñolas N, Ferrer F, Agustí C, Sanchez M, Maria Gimferrer J, Lomeña F, Campayo M, Jeremic B.
    J Thorac Oncol; 2011 Jan 27; 6(1):79-85. PubMed ID: 21150466
    [Abstract] [Full Text] [Related]

  • 32. Progress in standard of care therapy and modest survival benefits in the treatment of non-small cell lung cancer patients in the Netherlands in the last 20 years.
    van der Drift MA, Karim-Kos HE, Siesling S, Groen HJ, Wouters MW, Coebergh JW, de Vries E, Janssen-Heijnen ML.
    J Thorac Oncol; 2012 Feb 27; 7(2):291-8. PubMed ID: 22157366
    [Abstract] [Full Text] [Related]

  • 33. Pharmacoeconomics of bisphosphonates for skeletal-related event prevention in metastatic non-breast solid tumours.
    Carter JA, Joshi AD, Kaura S, Botteman MF.
    Pharmacoeconomics; 2012 May 27; 30(5):373-86. PubMed ID: 22500986
    [Abstract] [Full Text] [Related]

  • 34. Real-world treatment patterns and costs in a US Medicare population with metastatic squamous non-small cell lung cancer.
    Davis KL, Goyal RK, Able SL, Brown J, Li L, Kaye JA.
    Lung Cancer; 2015 Feb 27; 87(2):176-85. PubMed ID: 25532680
    [Abstract] [Full Text] [Related]

  • 35. Long-term outcome after en bloc resection of non-small-cell lung cancer invading the pulmonary sulcus and spine.
    Collaud S, Waddell TK, Yasufuku K, Pierre AF, Darling GE, Cypel M, Rampersaud YR, Lewis SJ, Shepherd FA, Leighl NB, Cho J, Bezjak A, Tsao MS, Keshavjee S, de Perrot M.
    J Thorac Oncol; 2013 Dec 27; 8(12):1538-44. PubMed ID: 24389435
    [Abstract] [Full Text] [Related]

  • 36. Surgical treatment of primary lung cancer with synchronous brain metastases.
    Billing PS, Miller DL, Allen MS, Deschamps C, Trastek VF, Pairolero PC.
    J Thorac Cardiovasc Surg; 2001 Sep 27; 122(3):548-53. PubMed ID: 11547308
    [Abstract] [Full Text] [Related]

  • 37. The role of comorbidity in the management and prognosis in nonsmall cell lung cancer: a population-based study.
    Nilsson J, Berglund A, Bergström S, Bergqvist M, Lambe M.
    Acta Oncol; 2017 Jul 27; 56(7):949-956. PubMed ID: 28486004
    [Abstract] [Full Text] [Related]

  • 38. Improving survival for stage IV non-small cell lung cancer: a surveillance, epidemiology, and end results survey from 1990 to 2005.
    Morgensztern D, Waqar S, Subramanian J, Gao F, Govindan R.
    J Thorac Oncol; 2009 Dec 27; 4(12):1524-9. PubMed ID: 19752759
    [Abstract] [Full Text] [Related]

  • 39. Cost-effectiveness of second-line chemotherapy for non-small cell lung cancer: an economic, randomized, prospective, multicenter phase III trial comparing docetaxel and pemetrexed: the GFPC 05-06 study.
    Vergnenegre A, Corre R, Berard H, Paillotin D, Dujon C, Robinet G, Crequit J, Bota S, Thomas P, Chouaid C, 0506 GFPC Team.
    J Thorac Oncol; 2011 Jan 27; 6(1):161-8. PubMed ID: 21150465
    [Abstract] [Full Text] [Related]

  • 40. Risk factors for skeletal-related events (SREs) and factors affecting SRE-free survival for nonsmall cell lung cancer patients with bone metastases.
    Ulas A, Bilici A, Durnali A, Tokluoglu S, Akinci S, Silay K, Oksuzoglu B, Alkis N.
    Tumour Biol; 2016 Jan 27; 37(1):1131-40. PubMed ID: 26276360
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.